Clinical Trial Update: An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 2]

View source ↗

Summary

Open-label extension study of Batoclimab in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is currently enrolling by invitation in Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Batoclimab (batoclimab)

Snippet

Sponsor: Immunovant Sciences GmbH | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Status: ENROLLING_BY_INVITATION